Group 1 - Xindong Company (02400) reported a positive earnings forecast, expecting revenue of at least RMB 3.05 billion for the first half of 2025, a year-on-year increase of approximately 37%, and a net profit of at least RMB 790 million, a year-on-year increase of about 215% [1] - Yimai Sunshine (02522) also announced a positive earnings forecast, expecting revenue between RMB 450 million to 480 million for the first half of the year, a year-on-year increase of approximately 8.77% to 16.03%, and a net profit of RMB 14.5 million to 16.5 million, a year-on-year increase of about 1350% to 1550% [1] - Tianli International Holdings (01773) plans to repurchase shares up to a total of HKD 200 million based on market conditions, believing that the share buyback plan is in the best interest of the company and its shareholders [2] Group 2 - Liaogang Co., Ltd. (02880) reported a total operating revenue of RMB 5.693 billion for the first half of 2025, a year-on-year increase of 5.93%, and a net profit attributable to shareholders of RMB 956 million, a year-on-year increase of 110.78% [2] - Yuan Zheng Technology (02488) reported a revenue of RMB 982 million for the first half of 2025, a year-on-year increase of 9.75%, and a net profit of RMB 195 million, a year-on-year increase of 27.74% [2] - Geekplus Technology (02590) expects revenue between RMB 995 million to 1.03 billion for the first half of the year, a year-on-year increase of 27% to 32%, while the net loss is expected to narrow significantly [3] Group 3 - Lee & Man Paper Manufacturing (02314) and other leading companies in the paper industry have initiated a price increase for various products starting August 1, indicating a significant acceleration in price adjustment frequency within the industry [3] - Xinda Biopharmaceutical (01801) announced that its innovative oral small molecule GLP-1R agonist IBI3032 has received IND approval from the FDA [4] - Heyu-B (02256) reported a revenue of RMB 612 million for the first half of the year, a year-on-year increase of 23.1%, and a net profit of RMB 328 million, a year-on-year increase of 58.84% [4] Group 4 - Bilibili (BILI.US) is expected to achieve a revenue growth of 20% year-on-year to RMB 7.3 billion in the second quarter, driven by stable performance in mobile games [5][6] - Li Auto (LI.US) launched the Li Xiang i8, with deliveries starting on August 20, and received positive outlooks from multiple institutions [6] - Xpeng Motors (XPEV.US) achieved a new monthly delivery record in July, delivering 36,717 smart electric vehicles, a year-on-year increase of 229% [7]

考虑到信达生物对授权许可的战略重视及其创新产品线，小摩提高对其潜在授权收入的预期，预计将占 信达生物未来总收入的5-7%。这种有利的销售组合亦正推动集团毛利率的扩张。同时，小摩表示，授 权许可已成为今年中国生物制药行业最重要的推动因素之一，该行认为信达生物是最能从这一趋势中受 益的公司之一。 智通财经APP获悉，摩根大通发布研报称，将集团早期资产的估值上调43%，因考虑到信达生物(01801) 的研发能力，且这些资产越来越得到市场认可。通过提高玛仕度肽(Mazdutide)(GLP-1/GIP)获批后的销 售成功率(PoS)、调整经营费用，上调目标价21%，由90港元升至109港元。并维持"增持"评级。 ...

信达生物(01801)涨超3%，截至发稿，涨3.12%，报95.8港元，成交额2.19亿港元。 消息面上，据信达生物官微消息，8月5日，公司宣布其研发的创新口服小分子GLP-1R激动剂IBI3032获 美国食品药物监督管理局(FDA)新药临床试验申请(IND)批准。 据介绍，IBI3032为信达生物自主研发的口服小分子GLP-1R激动剂，偏向性激活cAMP信号通路，基于 全球目前成熟验证的分子骨架且具有完全自主知识产权。IBI3032的I期临床试验将在中美同步推进，将 于2025年下半年开始在健康受试者及超重或肥胖人群中给药。信达生物正在迅速以玛仕度肽为基石在代 谢管线进行布局拓展，IBI3032临床研究启动是代谢产品矩阵进化的重要一步。 目前，IBI3032的新药临床试验申请(IND)已经获得中国国家药品监督管理局(NMPA)受理和美国FDA食 品药物监督管理局(FDA)批准，计划将在2025年下半年启动中美I期临床研究。 ...

智通财经APP获悉，信达生物(01801)涨超3%，截至发稿，涨3.12%，报95.8港元，成交额2.19亿港元。 据介绍，IBI3032为信达生物自主研发的口服小分子GLP-1R激动剂，偏向性激活cAMP信号通路，基于 全球目前成熟验证的分子骨架且具有完全自主知识产权。IBI3032的I期临床试验将在中美同步推进，将 于2025年下半年开始在健康受试者及超重或肥胖人群中给药。信达生物正在迅速以玛仕度肽为基石在代 谢管线进行布局拓展，IBI3032临床研究启动是代谢产品矩阵进化的重要一步。 目前，IBI3032的新药临床试验申请(IND)已经获得中国国家药品监督管理局(NMPA)受理和美国FDA食 品药物监督管理局(FDA)批准，计划将在2025年下半年启动中美I期临床研究。 消息面上，据信达生物官微消息，8月5日，公司宣布其研发的创新口服小分子GLP-1R激动剂IBI3032获 美国食品药物监督管理局(FDA)新药临床试验申请(IND)批准。 ...

SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to initiate a Phase 1 clinical trial of IBI3032, the co ...

每经AI快讯，8月4日，香港交易所信息显示，贝莱德（BlackRock）在信达生物H股的持股比例于7月29 日从4.70%升至5.17%。 ...

Core Viewpoint - The report from Guotai Haitong indicates that 2025 will be the year of commercialization for domestically developed innovative weight loss drugs with global competitiveness, following the first prescription issued for Innovent Biologics' injection of Ma Shidu peptide on July 3, marking a significant milestone in China's innovative weight loss drug development [1]. Industry Progress - Domestic innovative drug development in the weight loss sector has made substantial progress, including: - Zhongsheng Pharmaceutical completed the enrollment of all participants in the Phase III clinical trial for RAY1225 on July 31, with the first participant enrolled in June, showcasing rapid and efficient progress. The bi-weekly dosing regimen demonstrated significant advantages, with a 15.05% average weight reduction over 24 weeks in the 9mg group from Phase II study data [1]. - United BioPharma's UBT37034 received FDA IND approval, which selectively targets neuropeptide Y2 receptors to reduce weight. Preclinical studies showed that UBT37034 combined with GLP-1 analogs significantly reduced weight, outperforming other investigational drugs [1]. Company Developments - Several domestic pharmaceutical companies have made significant advancements in their weight loss drug pipelines: - LaiKai Pharmaceuticals received FDA approval for the clinical trial IND application of LAE103 on July 31, fully laying out the ActRIIA+B pathway [2]. - Gilead Sciences is expected to obtain 12-week Phase IIa data for ASC30 by Q1 2026 [2]. - Innovent Biologics' small molecule GLP-1 drug IBI3032 had its clinical trial application accepted by NMPA on July 16 [2]. - HengRui Medicine reported an average weight loss of 19.2% in the 6mg dose group during a 48-week Phase III trial, with plans to submit a new drug application soon [2]. Collaborations and Licensing - In 2023, several domestic pharmaceutical companies completed multiple licensing and collaboration deals related to weight loss drugs: - On July 30, CSPC Pharmaceutical Group licensed its oral GLP-1 small molecule SYH2086 to Madrigal Pharma for global development, production, and commercialization outside of China, with a total deal value of $2.075 billion, including a $120 million upfront payment [3]. - Borui Pharmaceutical reached a collaboration agreement with China Resources Sanjiu for the development, registration, production, and commercialization of BGM0504 injection in mainland China [3].

（股份代號：1801） 董事會召開日期 信達生物製藥（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公司將於 2025年8月27日（星期三）舉行董事會會議，以考慮及批准（其中包括）本公司及其 附屬公司截至2025年6月30日止六個月之中期業績及其發佈，並考慮建議派發中 期股息（如有）。 承董事會命 信達生物製藥 主席兼執行董事 俞德超博士 中國，香港，2024年8月4日 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 信達生物製藥 INNOVENT BIOLOGICS, INC. （於開曼群島註冊成立的有限公司） 於本公告刊發日期，董事會包括主席兼執行董事俞德超博士及執行董事奚浩先生 及張倩女士；及獨立非執行董事Charles Leland Cooney博士、許懿尹女士、Gary Zieziula先生、陸舜博士及陳樹云先生。 ...

"创新药已从'主题投资'转向'产业趋势投资'。"某公募基金医药行业研究员表示，政策端，医保谈判简化、审评审 批加速等改革持续落地；技术端，ADC（抗体偶联药物）、双抗、细胞治疗等前沿领域进入成果收获期；资本 端，美联储加息周期接近尾声，全球生物医药投融资环境回暖，共同构成了本轮行情的底层逻辑。 从"至暗时刻"到"聚光灯下"，医药行业的反转行情印证了"创新驱动增长"的长期逻辑。（水手） 医药基金"王者归来"，单月最高涨34%。板块的强劲表现直接反映在基金净值上。Wind数据显示，截至7月31日， 全市场200余只医药主题基金（AC份额合并计算）中，超过80%年内实现正收益。其中，永赢医药健康A以34.2% 的单月涨幅领跑，华富健康文娱A、中银创新医疗A等7只基金涨幅超30%，形成明显的"赚钱效应"。 拉长时间维度看，医药基金的复苏势头更为显著。年内业绩排名前十的主动权益类基金中，中银创新医疗A、融 通健康产业A等9只产品均聚焦医药领域，与去年同期的"无人问津"形成鲜明对比。某头部基金公司市场部负责人 透露："近期渠道调研显示，投资者对医药基金的关注度提升至2021年以来的最高水平，新发基金中医疗健康主题 占比超 ...

Group 1 - On August 1, the Hong Kong stock market saw a net inflow of 12.207 billion HKD from northbound trading, with 5.575 billion HKD from the Shanghai Stock Connect and 6.632 billion HKD from the Shenzhen Stock Connect [2] - The most bought stocks included the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and Xiaomi Group-W (01810), while the most sold stocks were Innovent Biologics (01801), Alibaba-W (09988), and SMIC (00981) [2][8] - Xiaomi Group-W reported over 30,000 vehicle deliveries in July, attributed to increased production capacity, with expectations of 400,000 to 500,000 vehicle sales by 2025 [6] Group 2 - In the technology sector, Tencent (00700), Meituan-W (03690), and Kuaishou-W (01024) saw net inflows of 8.36 billion, 7.66 billion, and 2.02 billion HKD respectively, while Alibaba-W faced a net outflow of 2.02 billion HKD [7] - InnoCare Pharma (02577) received a net inflow of 3.63 billion HKD after being listed as a partner by NVIDIA for its 800V DC power architecture, which is designed for AI data centers [7] - The overall sentiment in the Hong Kong market remains positive, with expectations of a structural uptrend driven by improving fundamentals and policy outlook [6][7]